Medical Information

Semaglutide is a GLP-1 receptor agonist, which is mainly used for blood glucose control in patients with type 2 diabetes. Its applicable population, restrictions and drug interactions should strictly follow the clinical guidelines to ensure the safety and effectiveness of drug use.

1. Applicable population

(1) Core indications: applicable to adult type 2 diabetes patients, as an auxiliary treatment for diet control and exercise, to improve blood sugar control.

(2) Special population: Elderly people do not need to adjust dosage, but need to be closely monitored; Pregnant women should use it with caution, while lactating women should use it with caution; The safety of children and adolescents has not yet been established.

2. Restrictive conditions

(1) Contraindications: It is forbidden for patients with smeglutide allergy, type 1 diabetes, and diabetes ketoacidosis.

(2) Caution: Patients with a history of pancreatitis, severe gastrointestinal diseases, or a personal or family history of medullary thyroid cancer should use with caution.

(3) Renal dysfunction: Mild to moderate renal dysfunction requires dose adjustment, while severe renal dysfunction requires careful use.

3. Drug interactions

(1) Hypoglycemic drugs: Combined use with insulin or sulfonylureas may increase the risk of hypoglycemia and require dosage adjustment.

(2) Oral medication: may delay the absorption of oral medications such as acetaminophen, it is recommended to take them intermittently.

(3) Other interactions: INR should be monitored when combined with warfarin, and dehydration risk should be noted when combined with diuretics.